Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 6/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | DDX3X | O00571 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | MMP1 | P03956 | 1/20 | 0.57 |
| ▸ | MMP2 | P08253 | 1/20 | 0.57 |
| ▸ | MMP9 | P14780 | 1/20 | 0.57 |
| ▸ | MMP8 | P22894 | 1/20 | 0.57 |
| ▸ | MMP13 | P45452 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | EDNRA | P25101 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2407197 | 0.86 | L3MBTL1 (0.66) | KDM4EALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL9302174 | 0.84 | MAPT (0.68) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL2265350 | 0.84 | MEN1 (0.68) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL13265932 | 0.83 | KMT2A (0.62) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL13265929 | 0.83 | MEN1 (0.62) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL29227834 | 0.80 | MAPT (0.65) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL30939451 | 0.80 | MAPT (0.65) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL4101284 | 0.79 | PGR (0.78) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL5032657 | 0.78 | L3MBTL1 (1.00) | ALDH1A1MEN1KMT2ALMNAL3MBTL1 | |
| SCHEMBL30939468 | 0.78 | MAPT (0.59) | MAPTKDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246915-A1 | AMINONAPHTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2024-07-25 | — | — | US | disclosed |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2024-03-05 | — | — | US | disclosed |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2024-03-05 | — | — | US | disclosed |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2024-03-05 | — | — | US | disclosed |
| EP-3324954-B1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | CALGENT BIOTECHNOLOGY CO LTD (TW) | 2022-03-09 | — | — | EP | disclosed |
| US-20200148643-A1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2020-05-14 | — | — | US | disclosed |
| US-20200148643-A1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2020-05-14 | — | — | US | disclosed |
| US-10577328-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | TAIPEI MEDICAL UNIVERSITY (TW) | 2020-03-03 | — | — | US | disclosed |
| US-10577328-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | TAIPEI MEDICAL UNIVERSITY (TW) | 2020-03-03 | — | — | US | disclosed |
| US-20180319749-A1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2018-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148643-A1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | UBQLN1, UBQLN2, PSMB1 | MAPT 406/4885KDM4E 2041/4885ALDH1A1 3039/4885 |
| US-10577328-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | PSMB1, UBQLN1, PSMB5 | MAPT 478/4885KDM4E 1143/4885ALDH1A1 2346/4885 |
| US-20180319749-A1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | UBQLN1, UBQLN2, PSMB1 | MAPT 406/4885KDM4E 2041/4885ALDH1A1 3039/4885 |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | UBQLN1, PSMB1, UBQLN2 | MAPT 1163/4885KDM4E 2018/4885ALDH1A1 2017/4885 |
| US-20240246915-A1 | AMINONAPHTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | UBQLN1, ADRM1, UBQLN2 | MAPT 703/4885KDM4E 2122/4885ALDH1A1 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.